# OGIVRI

NDC: 67457-991
Generic name: trastuzumab
Labeler / Manufacturer: Mylan Institutional LLC
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes: INTRAVENOUS
Marketing started: 20191129
Marketing ended: 20270228
FDA application: BLA761074

## Active ingredients

- TRASTUZUMAB: 150 mg/7.4mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"67457-991"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=67457-991